Table 5.

Utility Values for Vision States and Disease Treatments.

State	Utility	Range tested	Source
Baseline	0.87	0.8 to 1.0	Brown et al. 30
Severe vision loss	0.66	0.5 to 0.77
Utility change, PRP treatment if no DME	−0.0075	−0.2 to +0.2	Hutton et al. 14
Utility change, PRP treatment if DME	−0.019	−0.2 to +0.2
Utility change, ranibizumab treatment if no DME	0.0095	−0.2 to +0.2)
Utility change, ranibizumab treatment if DME	0.0335	−0.2 to +0.2
Death	0	N/A

Note: Severe vision loss defined as VA 20/200 or worse in the better-seeing eye.

DME, diabetic macular edema; DR, diabetic retinopathy; PRP, pan-retinal photocoagulation.